Risk factor and mechanism of reactivation of hepatitis B virus following systemic chemotherapy

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591428
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Nagoya City University
• Principal Investigator: KUSUMOTO Shigeru 名古屋市立大学, 医学(系)研究科(研究院), 講師 (90423855)
• Co-Investigator(Renkei-kenkyūsha): TANAKA Yasuhito 名古屋市立大学, 大学院医学研究科, 教授 (90336694)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: B型肝炎ウイルス再活性化

Outline of Final Research Achievements

Reactivation of hepatitis B virus is a potentially fatal complication following systemic chemotherapy. HBV reactivation may occur not only in patients with seropositive for HBsAg, but also in patients with seropositive for anti-HBc and/or anti-HBs (HBV resolved infection). This study demonstrated that if a potentially immune-enhancing drug is used for HBsAg-positive cancer patients with high HBV DNA levels, HBV reactivation-related death may occur despite antiviral prophylaxis before hepatitis onset. This study also showed that HBV reactivation may occur not only in patients with B-cell lymphoma who received rituximab-containing chemotherapy, but also with T-cell lymphoma. In near future, new molecular target drugs may change the risk of HBV reactivation.

Free Research Field

血液・腫瘍内科学